lunes, 10 de diciembre de 2012

Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer, Guidelines from National Institute for Clinical Excellence

59789.pdf

http://www.nice.org.uk/nicemedia/live/13773/59789/59789.pdf

Double helix with text: Genomics & Health Impact Update

Lung Cancer, Genomics, Prevention & Treatment

No hay comentarios:

Publicar un comentario